HUTCHMED Shares Climb After China's Conditional Approval of ORPATHYS for MET‑Amplified Gastric Cancer
HUTCHMED's stock rose after China’s National Medical Products Administration granted conditional approval to ORPATHYS (savolitinib) for patients with MET‑amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma who have exhausted at least two prior systemic therapies. The decision, supported by a pivotal Phase II study, marks t…